Diabetic Peripheral Neuropathy - Global Pipeline Review (H1 2019) by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 28, 2019--
The “Diabetic Peripheral Neuropathy - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Diabetic Peripheral Neuropathy - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 7, 3 and 9 respectively.
Reasons to Buy
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ekudu6
View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005267/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs ,Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/28/2019 04:56 AM/DISC: 05/28/2019 04:56 AM